The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Chymase Inhibitor as a Novel Therapeutic Agent for Non-alcoholic Steatohepatitis
|
|---|---|
| Published in |
Frontiers in Pharmacology, February 2018
|
| DOI | 10.3389/fphar.2018.00144 |
| Pubmed ID | |
| Authors |
Shinji Takai, Denan Jin |
| Abstract |
Non-alcoholic steatohepatitis (NASH) is characterized by inflammation and fibrosis, in addition to steatosis, of the liver, but no therapeutic agents have yet been established. The mast cell protease chymase can generate angiotensin II, matrix metalloproteinase-9 and transforming growth factor-β, all of which are associated with liver inflammation or fibrosis. In animal models of NASH, augmented chymase has been observed in the liver. In histological analysis, chymase inhibitor prevented hepatic steatosis, inflammation, and fibrosis. Chymase inhibitor also attenuated the augmentation of angiotensin II, matrix metalloproteinase-9, and transforming growth factor-β observed in the liver of NASH. Oxidative stress, inflammatory markers, and collagen were attenuated by chymase inhibition. Moreover, chymase inhibitor showed a mitigating effect on established NASH, and survival rates were significantly increased by treatment with chymase inhibitor. In this review, we propose that chymase inhibitor has potential as a novel therapy for NASH. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 13 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 31% |
| Researcher | 2 | 15% |
| Student > Doctoral Student | 1 | 8% |
| Student > Master | 1 | 8% |
| Student > Ph. D. Student | 1 | 8% |
| Other | 0 | 0% |
| Unknown | 4 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 15% |
| Agricultural and Biological Sciences | 2 | 15% |
| Biochemistry, Genetics and Molecular Biology | 1 | 8% |
| Veterinary Science and Veterinary Medicine | 1 | 8% |
| Immunology and Microbiology | 1 | 8% |
| Other | 1 | 8% |
| Unknown | 5 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 March 2022.
All research outputs
#7,375,268
of 23,243,271 outputs
Outputs from Frontiers in Pharmacology
#3,166
of 16,677 outputs
Outputs of similar age
#128,443
of 331,634 outputs
Outputs of similar age from Frontiers in Pharmacology
#76
of 341 outputs
Altmetric has tracked 23,243,271 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 16,677 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 331,634 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.
We're also able to compare this research output to 341 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.